Clinical trials: IgAN - IgA Nephropathy
IgA Nephropathy
Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.
The purpose of this study is to determine whether Multi-glycoside of Tripterygium Wilfordii HOOK. f. is effective and safe in the treatment of IgA nephropathy.
- Trial name
- NCT02187900
- Testing
- Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH), Mycophenolate mofetil (MMF)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Second Xiangya Hospital of Central South University
IgA Nephropathy
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters.
- Trial name
- NCT02052219
- Testing
- Blisibimod
- Sponsor
- Anthera Pharmaceuticals
IgAN, Immunoglobulin A Nephropathy (IgAN)
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.
- Conditions
- IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
- Trial name
- HS-10542 (NCT07474636)
- Testing
- HS-10542 High Dose, HS-10542 Low Dose
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Primary IgA Nephropathy
The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.
MIMIGA Study Title: Modification of Intestinal Microbiome in Patients with Primary IgA Nephropathy (IgAN) Objective: To evaluate whether supplementation with short-chain fatty acids (SCFAs)-specifically sodium butyrate-can reduce…
- Trial name
- MIMIGA (NCT07750249)
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- University Hospital, Martin
IgA Nephropathy
Effect of Finerenone in IgA Nephropathy
The aim of this trial is to conduct a randomized, multicenter, placebo-controlled, double-blind clinical trial to determine the safety and efficacy of Finerenone in reducing proteinuria and protecting renal function in patients…
- Trial name
- FIGHT (NCT06580288)
- Testing
- Finerenone
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
IGA Nephropathy
Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy
TO ASSESS THE EFFICACY OF THE RENIN ANGIOTENSIN SYSTEM PLUS STEROIDS TO DECREASE THE AMOUNT OF PROTEINURIA IN IGA NEPHROPATHY
- Trial name
- NCT00367562
- Testing
- ENALAPRIL VALSARTAN METHYLPREDNISONE
- Where
- Argentina
- Volunteers
- 20 people
- Sponsor
- Hospital Britanico
IgA Nephropathy
Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
This study is an extended follow-up of the study (ClinicalTrials.gov ID: NCT01758120)-Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.
- Trial name
- e-TOPplus (NCT03218852)
- Testing
- prednisone and cyclophosphamide, prednisone alone
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Guangdong Provincial People's Hospital
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy…
- Trial name
- NCT06004947
- Testing
- CCX168, Midazolam, Celecoxib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
IgA Nephropathy
Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
Immunoglobulin A (IgA) nephropathy is the common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular…
- Trial name
- NCT00599963
- Testing
- paricalcitol
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
IgA Nephropathy
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)
This Phase 3, open-label study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of sibeprenlimab administered subcutaneously every 4 weeks in pediatric…
- Trial name
- NCT07770815
- Testing
- Sibeprenlimab, Standard of care
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy Subjects
Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
This single-center, open-label, randomized, single and multiple-dose, 3-way sequential study at 3 dose levels will be performed in healthy subjects. Subjects will be randomized to 1 of the 3 dose levels.
- Trial name
- NCT05562362
- Testing
- RE-021, sparsentan
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Travere Therapeutics, Inc.
IgA Nephropathy
Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath
IgA nephropathy(IgAN) is the highest incidence of kidney pathology in the primary nephropathy. In terms of differences in prognosis, severe IgA nephropathy,one of the most main primary renal disease,could cause the uremia.
- Trial name
- NCT01879514
- Testing
- Chinese Herb Prescription Granule plus prednisone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
IgA Nephropathy, Immunoglobulin A Nephropathy
Atrasentan in Patients With IgA Nephropathy
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
- Trial name
- ALIGN (NCT04573478)
- Testing
- Atrasentan, Zigakibart
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy (IgAN), Berger Disease
Monthly Dosing of Atacicept in IgAN
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
- Trial name
- NCT07020923
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Vera Therapeutics, Inc.
Primary IgA Nephropathy
Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy
NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade.
- Trial name
- NCT06982040
- Testing
- NTQ5082 capsules 100 mg, NTQ5082 capsules 200 mg, NTQ5082 capsules 300 mg
- Volunteers
- 80 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
IgA Nephropathy (IgAN)
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
: IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy…
- Trial name
- NCT07056595
- Testing
- Finerenone
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Botkin Hospital
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month trial of MMF treatment alone.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446251
- Testing
- Rituximab, Mycophenolate mofetil (MMF)
- Volunteers
- 14 people
- Sponsor
- University of Washington
IgA Nephropathy
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
This is an open-label Phase 2a clinical study designed to evaluate the safety and efficacy of AVB-S6-500 in patients with IgA Nephropathy (IgAN). Approximately 24 patients will be enrolled.
- Trial name
- NCT04042623
- Testing
- AVB-S6-500
- Where
- 2 sites in United States, Ukraine
- Volunteers
- 1 people
- Sponsor
- Aravive, Inc.
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
IgA Nephropathy
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases
- Trial name
- NCT06774664
- Testing
- SCTC21C
- Where
- 20 sites in China
- Volunteers
- 99 people
- Sponsor
- Sinocelltech Ltd.